Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 9.08B 7.93B 7.33B 6.78B 12.76B 872B 12.99B 87.46B 34.31B 427B 34.1B 33.34B 1,470B P/E 2026 *
-15.2x
P/E 2027 * -31.1x
Enterprise Value 8.83B 7.71B 7.13B 6.59B 12.4B 848B 12.63B 85.02B 33.36B 415B 33.15B 32.42B 1,429B EV / Sales 2026 *
9.93x
EV / Sales 2027 * 6.43x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day-1.30%
1 week-36.47%
Current month-32.33%
1 month-27.45%
3 months-30.15%
6 months-30.51%
Current year-32.18%
1 week 53.51
Extreme 53.51
70.35
1 month 53.51
Extreme 53.51
86.74
Current year 53.51
Extreme 53.51
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.95
Extreme 23.95
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-30Free

Director

7,670 0.0046%
06-30Free

Director

7,670 0.0046%
06-30Fiscal year

Director

42,224 0.0255%
Change 5-day change 1-year change 3-year change Capi.($)
-1.31%-36.47%+27.75%+27.14% 9.08B
-0.07%+1.68%+3.37%+7.65% 50.35B
-0.92%-3.41%+384.81%+588.86% 39.32B
+1.19%+3.67%+33.99%-4.56% 34.69B
+1.96%+3.59%+15.95%+58.02% 34.08B
-1.31%-3.03%+2.51%+25.24% 26.63B
-0.12%-4.66% - - 16.49B
-0.49%+0.82%+71.52%+116.83% 15.31B
+1.39%+4.32%+16.06%+19.10% 13.8B
+0.27%+2.16%+16.11%-31.02% 12.87B
Average +0.08%-4.38%+63.56%+89.70% 25.26B
Weighted average by Cap. +0.17%-2.01%+79.90%+118.30%

Financials

2026 *2027 *
Net sales 889M 777M 718M 664M 1.25B 85.4B 1.27B 8.57B 3.36B 41.82B 3.34B 3.27B 144B 1.4B 1.22B 1.13B 1.04B 1.97B 134B 2B 13.47B 5.29B 65.77B 5.25B 5.14B 226B
Net income -596M -521M -481M -445M -837M -57.22B -852M -5.74B -2.25B -28.02B -2.24B -2.19B -96.48B -296M -259M -239M -221M -417M -28.47B -424M -2.86B -1.12B -13.94B -1.11B -1.09B -48B
Net Debt -252M -221M -204M -188M -355M -24.25B -361M -2.43B -954M -11.88B -948M -927M -40.89B -86.16M -75.29M -69.6M -64.31M -121M -8.28B -123M -830M -326M -4.05B -324M -316M -13.95B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-15 US$53.65 -2.33% 374,378
26-07-14 US$54.93 -3.21% 4,700,265
26-07-13 US$56.75 -2.58% 5,097,949
26-07-10 US$58.25 -9.37% 11,444,106
26-07-09 US$64.27 -23.90% 20,447,626
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
54.93USD
Average target price
92.45USD
Spread / Average Target
+68.31%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock